Abstract
The market for psychotherapeutics drugs is about to change dramatically -- and
serious pharmaceutical market watchers will want to be prepared. Kalorama' s
World Market for Psychotherapeutic Drugs is the most exhaustive guide
available to this booming market and the direction it is headed in the next
four years.
Psychotherapeutics treat conditions classified as abnormal behavior, thoughts
and feelings that persist for a determined amount of time causing distress or
emotional/physical impairment. Depression, anxiety, psychosis, ADHD and
nicotine and drug dependence are among the conditions psychotherapeutics
treat. Well-known brands such as Prozac™, Zoloft™ and Ritalin
™ have made this a $37 billion market. And according to Kalorama' s
research, revenues from this area will grow more than 50% by 2010.
The World Market For Psychotherapeutic Drugs covers this market completly
including an overviews; surveys of thsee e key players, geographic market
breakdowns, and revenue forecasts to 2010 in these key market segments:
- Antidepressants
- Antipsychotics/Antimanics
- Antianxiety Drugs
- Stimulants and Non-stimulants for ADHD
- Smoking Cessation Drugs, Drug Dependence Treatments and Other
Psychotherapeutics
In every category of psychotherapeutics, new competitors are emerging.
Kalorama' s report provides profiles of thirty-six new psychotherapeutic
drugs in the pipeline, their expected approval status, and how they may
shake up the marketplace - as well as a complete discussion of the issues and
trends that will effect psychotherapeutics. The report also includes current
issues and trends affecting the industry including the increasing number of
additional indications pharma companies are seeking for their brands and
success stories in this area.
As part of our complete coverage, the following companies are profiled:
- Astellas Pharma, Inc.
- AstraZeneca Plc
- Biovail Corporation
- Bristol-Myers Squibb
- Eli Lilly & Company
- Forest Laboratories, Inc.
- GlaxoSmithKline Plc
- H. Lundbeck A/S
- Johnson & Johnson
- Otsuka Pharmaceutical Co. Ltd.
- Pfizer, Inc.
- Shire Pharmaceuticals Group Plc
- Wyeth
Kalorama' s trusted information-gathering process provides the most accurate
study of the market for anti-depressants, anti-anxiety drugs, ADHD treatments
and other psychotherapeutic drugs available today. Information and analysis
presented in this report is based on extensive interviews with senior
management of top companies and in the psychotherapeutics market. While
financial reports, major research literature and government information is
culled, information is corroborated and key market insights originate from
interviews with industry leaders.
Product managers, marketing managers, business development executives,
advertising agency or investment firm executives, as well as information and
research center librarians are among the individuals who will find this survey
of the changing psychotherapeutics market essential.
View Cart
